Technoview Arixtra CON L



Attachment 18

DQ2600.02

3U21C01.02

Date

REF

5090012-RUO

LOT

3U21C01.02

 \mathbf{Z}

2025-12-31

| Analytical Procedures | | Requirement | Result | |
|-----------------------|---|--|------------|----|
| visual inspection | Cap color | red | confirmed | ОК |
| | Vial type | clear glass vial | confirmed | ОК |
| | Vial label | according to packaging SOP | confirmed | ОК |
| | Vial barcode | according to packaging SOP | confirmed | ОК |
| | Box label | according to packaging SOP | confirmed | ОК |
| | Box barcode | according to packaging SOP | confirmed | ОК |
| | Package insert | present | confirmed | ОК |
| | Batch table | present | confirmed | ОК |
| | Appearance before reconstitution | buff colored plug of lyophilized material | confirmed | ОК |
| | Appearance after reconstitution | amber colored liquid | confirmed | ОК |
| | HBsAg / HBsAg | Negative | Negative | |
| Virology | HIV-Ak / HIV-Ab | Negative | Negative | |
| | HCV-AK / HCV-Ab | Negative | Negative | ОК |
| The testing methods a | applied were FDA-approved or CE marked. | 1950 | | |
| Recovery of control | | 0.34 - 0.64 μg/mL | 0.50 μg/mL | ОК |

| Prepared by | Lugas HOMENCZ | 17. JAN. 2024 |
|-------------|------------------|---------------|
| | | Date |
| | Maulid BALISCHER | |
| Approved by | Maylis RAUSCHER | 17. JAN. 2024 |

Confidential